Producing anti-inflammatory macrophages by nanoparticle-triggered clustering of mannose receptors
Source abstract
Abstract
Macrophages are highly plastic cells that can either mediate or suppress inflammation, depending on their cellular phenotype and cytokine secretion. Inducing macrophages from an inflammatory ('M1') to anti-inflammatory ('M2') phenotype has significant implications for the treatment of inflammatory diseases and regeneration of injured tissues. Although certain cytokines, such as interleukin-4 and -13, are known to induce this phenotypic switch, their therapeutic use in vivo has both safety and efficacy concerns. Here, we demonstrate an alternative approach to change macrophage phenotype from M1 to M2, through inducing the clustering of mannose receptors (MR) on the cell surface, by using carbohydrate-presenting substrates. We prepared and screened glucomannan-decorated silicon oxide of different sizes ranging from 10 to 1000 nm, and identified one type (KSiNP30) that could potently induce MR clustering on macrophages and thereby stimulated the cells into an M2 phenotype - as an unexpected consequence of MR activation. Further administration of KSiNP30 in a murine model of inflammatory bowel disease efficiently alleviated the colitis symptoms, indicating the translational potential of our finding for therapeutic applications. In summary, we report for the first time an approach to modulate cellular immune responses by manipulating the assembly of cell-surface receptors, without the aid of cytokines. Our approach may provide insights for the development of new anti-inflammatory therapies.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Immunotherapy and Immune Responses · Phagocytosis and Immune Regulation · Immune cells in cancer
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (56)
Show source-provided references
1. Macrophage plasticity and polarization: in vivo veritas10.1172/JCI59643 ↗
2. Macrophage biology in development, homeostasis and disease10.1038/nature12034 ↗
3. Cellular metabolism and macrophage functional polarization10.3109/08830185.2014.969421 ↗
4. Differentiation and gene expression profile of tumor-associated macrophages10.1016/j.semcancer.2012.02.002 ↗
5. The regulation of IL-10 production by immune cells10.1038/nri2711 ↗
6. C-type lectin receptors on dendritic cells and Langerhans cells10.1038/nri723 ↗
7. From pattern recognition receptor to regulator of homeostasis: the double-faced macrophage mannose receptor10.1615/CritRevImmunol.v24.i3.20 ↗
8. Role of the mannose receptor in the immune response10.2174/1566524013363645 ↗
9. Structure of a C-type carbohydrate recognition domain from the macrophage mannose receptor10.1074/jbc.M002366200 ↗
10. Mannose receptor regulation of macrophage cell migration10.1189/jlb.0107053 ↗
11. Mannose-binding lectin enhances Toll-like receptors 2 and 6 signaling from the phagosome10.1084/jem.20071164 ↗
12. miR-511-3p modulates genetic programs of tumor-associated macrophages10.1016/j.celrep.2011.12.005 ↗
13. Lung cell-specific modulation of LPS-induced TLR4 receptor and adaptor localization10.4161/cib.29053 ↗
14. Nanoscale organization of the pathogen receptor DC-SIGN mapped by single-molecule high-resolution fluorescence microscopy10.1002/cphc.200700169 ↗
15. Exploring 'new' bioactivities of polymers at the nano-bio interface10.1016/j.tibtech.2014.11.002 ↗
16. C-type lectin receptors orchestrate antifungal immunity10.1038/ni.2369 ↗
17. Cell type-specific differences in beta-glucan recognition and signalling in porcine innate immune cells10.1016/j.dci.2014.10.005 ↗
18. Beta-glucan-activated human B lymphocytes participate in innate immune responses by releasing proinflammatory cytokines and stimulating neutrophil chemotaxis10.4049/jimmunol.1500559 ↗
19. Calcium-sensing receptors signal constitutive macropinocytosis and facilitate the uptake of NOD2 ligands in macrophages10.1038/ncomms11284 ↗
20. Activation of the innate immune receptor Dectin-1 upon formation of a 'phagocytic synapse'10.1038/nature10071 ↗
21. The mannose receptor10.1189/jlb.0512231 ↗
22. Interleukin-10 increases mannose receptor expression and endocytic activity in monocyte-derived dendritic cells10.1007/s005990050037 ↗
23. Carboxymethyl modification of konjac glucomannan affects water binding properties10.1016/j.carbpol.2015.05.001 ↗
24. Size-dependent absorption mechanism of polymeric nanoparticles for oral delivery of protein drugs10.1016/j.biomaterials.2012.07.063 ↗
25. Anti-tumor immune responses of tumor-associated macrophages via toll-like receptor 4 triggered by cationic polymers10.1016/j.biomaterials.2012.09.062 ↗
26. Weischenfeldt · 2008
27. Optimizing sgRNA structure to improve CRISPR-Cas9 knockout efficiency10.1186/s13059-015-0846-3 ↗
28. Genome-scale CRISPR-Cas9 knockout screening in human cells10.1126/science.1247005 ↗
29. Quantitative profiling of the protein coronas that form around nanoparticles10.1038/nprot.2014.139 ↗
30. Antibodies to interleukin 12 abrogate established experimental colitis in mice10.1084/jem.182.5.1281 ↗
31. Targeting delivery of anti-TNFalpha oligonucleotide into activated colonic macrophages protects against experimental colitis10.1136/gut.2009.184556 ↗
32. Influence of the mannose receptor in host immune responses10.1016/j.imbio.2008.11.004 ↗
33. An orally administrated nucleotide-delivery vehicle targeting colonic macrophages for the treatment of inflammatory bowel disease10.1016/j.biomaterials.2015.01.013 ↗
34. Targeted depletion of tumour-associated macrophages by an alendronate-glucomannan conjugate for cancer immunotherapy10.1016/j.biomaterials.2014.09.007 ↗
35. Synthesis and properties of novel hydrogels from oxidized konjac glucomannan crosslinked gelatin for in vitro drug delivery10.1016/j.carbpol.2007.09.023 ↗
36. Genome engineering using the CRISPR-Cas9 system10.1038/nprot.2013.143 ↗
37. Negative regulatory role of mannose receptors on human alveolar macrophage proinflammatory cytokine release in vitro10.1189/jlb.1204699 ↗
38. Cross-linking of the mannose receptor on monocyte-derived dendritic cells activates an anti-inflammatory immunosuppressive program10.4049/jimmunol.171.9.4552 ↗
39. The mannose receptor in regulation of helminth-mediated host immunity10.3389/fimmu.2017.01677 ↗
40. Next-generation sequencing reveals low-dose effects of cationic dendrimers in primary human bronchial epithelial cells10.1021/nn5061783 ↗
41. Effect of cytochalasin B on the adhesion of mouse peritoneal macrophages10.1083/jcb.69.2.407 ↗
42. IL-4Ralpha-independent expression of mannose receptor and Ym1 by macrophages depends on their IL-10 responsiveness10.1371/journal.pntd.0000689 ↗
43. Key role of MEK/ERK pathway in sustaining tumorigenicity and in vitro radioresistance of embryonal rhabdomyosarcoma stem-like cell population10.1186/s12943-016-0501-y ↗
44. The role of macrophages in inflammatory bowel diseases
45. Multivalent ligands control stem cell behaviour in vitro and in vivo10.1038/nnano.2013.205 ↗
46. Accelerating the translation of nanomaterials in biomedicine10.1021/acsnano.5b03569 ↗
47. Matrix crosslinking forces tumor progression by enhancing integrin signaling10.1016/j.cell.2009.10.027 ↗
48. Nanoscale organization and dynamics of the siglec CD22 cooperate with the cytoskeleton in restraining BCR signalling10.15252/embj.201593027 ↗
49. Functional role of T-cell receptor nanoclusters in signal initiation and antigen discrimination (vol 113, pg E5454, 2016)
50. Synthetic multivalent ligands in the exploration of cell-surface interactions10.1016/S1367-5931(00)00153-8 ↗
51. Insights into collagen uptake by C-type mannose receptors from the crystal structure of Endo180 domains 1-410.1016/j.str.2015.09.004 ↗
52. Nanoclustering as a dominant feature of plasma membrane organization10.1242/jcs.146340 ↗
53. Harnessing nanotopography and integrin-matrix interactions to influence stem cell fate10.1038/nmat3980 ↗
54. Physical and mechanical regulation of macrophage phenotype and function10.1007/s00018-014-1796-8 ↗
55. Modulation of macrophage phenotype by cell shape10.1073/pnas.1308887110 ↗
56. Inflammatory bowel disease10.1038/540S97a ↗